Your browser doesn't support javascript.
loading
Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: Real-world data from two lipid units.
Scicali, Roberto; Mandraffino, Giuseppe; Di Pino, Antonino; Scuruchi, Michele; Ferrara, Viviana; Squadrito, Giovanni; Purrello, Francesco; Piro, Salvatore.
Afiliação
  • Scicali R; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Mandraffino G; Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Lipid Center, University of Messina, Messina, Italy. Electronic address: gmandraffino@unime.it.
  • Di Pino A; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Scuruchi M; Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Lipid Center, University of Messina, Messina, Italy.
  • Ferrara V; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Squadrito G; Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Lipid Center, University of Messina, Messina, Italy.
  • Purrello F; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Piro S; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Nutr Metab Cardiovasc Dis ; 31(12): 3401-3406, 2021 11 29.
Article em En | MEDLINE | ID: mdl-34627693
BACKGROUND AND AIMS: Neutrophil-to-lymphocyte ratio (NLR) is a novel inflammatory biomarker strongly associated with atherosclerotic cardiovascular disease (ASCVD). Our aim was to evaluate the role of NLR on pulse wave velocity (PWV) after adding-on proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9-i) in familial hypercholesterolemia (FH) subjects with ASCVD. METHODS AND RESULTS: In this prospective observational study, we evaluated 45 FH subjects with ASCVD on high-intensity statins plus ezetimibe and with an off-target LDL-C. Study population was divided into two groups according to the mean value of NLR. All patients received PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i. After six months of add-on PCSK9-i therapy, a significant reduction of TC, LDL-C, Non-HDL-C, Lp(a) and ApoB plasma levels was observed in the two groups; while low-NLR group exhibited a significant PWV reduction after six-month therapy with PCSK9-i (Δ -16.2%, p < 0.05), no significant changes in PWV were observed in the high-NLR group. CONCLUSIONS: Only FH subjects with low-NLR experienced a significant reduction of PWV after PCSK9-i. Our findings suggest a role of NLR in predicting PCSK9-i effect in FH subjects with ASCVD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aterosclerose / Inibidores de PCSK9 / Hiperlipoproteinemia Tipo II Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aterosclerose / Inibidores de PCSK9 / Hiperlipoproteinemia Tipo II Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article